CEO / COO / President / General Manager
Scientific and Business Executive with a record of achieving aggressive goals in large pharmaceutical, start-up biotechnology, and medical device companies by positioning capital, people, intellectual property, systems, and internal disciplines for successful long term growth.
Accomplished entrepreneur with business leadership experience and solid scientific background to drive products from bench to commercialization. Achieved aggressive product development goals by positioning capital, people, intellectual property, systems, corporate partnerships, and internal disciplines for successful long-term growth. Key player in development of two FDA approved products (DepoCyt and DepoMorphine) from bench to commercial launch.
Areas of Leadership Expertise:
Visionary & Strategic Leadership
Aggressive Product Development
IPO & Shareholders Value
Debt Restructuring▪Team Building & Leadership
Company Image & Visibility
Seed and Future Fund Raising
Mergers & Acquisitions▪Business Development
Corporate Partners & JVs
Product Pipeline Development
Strategic Alliances / Equity Investors
Product Development Expertise:
Cell Transplantation Therapy
Drug Delivery and Biopolymers
Mergers & Acquisitions: As President and CEO of Vyteris, Inc., orchestrated the merger and integration of MediSync BioServices Inc. in 2011, and secured Board approval to exit the transdermal drug delivery business, monetize assets, substantially reduce total liabilities, and raise $25MM in equity capital for the purpose of acquiring 4 contract research organizations (CROs).
Seed and Future Fund Raising: Led Microislet, Inc. from start-up to a successful public company, negotiating $25MM in startup equity financing and generating additional funds by taking company public, resulting in market cap increase of $80MM (average) in 24 months and shares traded on the American Stock Exchange. Secured an additional $2MM from NIH and $500K from Juvenile Diabetes Foundation. Founded Protagenic Therapeutics, Inc., securing $2MM in seed financing from influential and established investors who are well-known in the industry. Orchestrated $25MM in equity capital for Vyteris.
Business Development: At Vyteris, Inc., established business development strategies, forged partnerships, and led strategic alliance discussions with major biopharmaceutical companies in the transdermal drug delivery market. In-licensed technologies to strengthen product offerings. As CEO, Director and Founder of Protagenic Therapeutics, Inc., negotiated an exclusive licensing agreement with the University of Toronto for a revolutionary therapeutic technology.
Public/ Private Company and Wall Street Experience: Served on both private and public company Boards of Directors; gained tremendous Wall Street experience bringing companies public and negotiating equity deals with investment banking firms, private equity and venture capital firms, and private investors.
VYTERIS INC. (OTC/BB: VYTR), Fair Lawn, NJ 2008 to 2011
President and CEO
PROTAGENIC THERAPEUTICS INC,, San Diego, CA 2006 to 2008
President and CEO, Director and Founder
MICROISLET, INC., San Diego, CA 2000 to 2006
President, COO and Co-Founder
MONSANTO, San Diego, CA 1998 to 2000
Director, Process Development
DEPOTECH CORPORATION, San Diego, CA 1994 to 1998
Associate Director – Process Development (1997 to 1998)
Manager – Process Development (1995 to 1997)
Senior Process Engineer (1994 to 1995)
DUPONT CENTRAL RESEARCH AND DEVELOPMENT, Wilmington, DE 1992 to 1994